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ligand based molecular staging predicts
prognosis in head and neck squamous cell
carcinoma partly due to deregulated
EGF- induced amphiregulin expression
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Abstract
Background: Increased expression of epidermal growth factor receptor (EGFR) and its ligands is associated with
poor prognosis and chemoresistance in many carcinoma types, but its role in head and neck squamous cell
carcinoma (HNSCC) is unclear. Our aim was to clarify whether mRNA expression of EGFR-ligands was linked to
prognosis and cisplatin resistance, and if so, which ligand was most important and how was the expression
regulated.
Methods: To examine the prognostic effect of EGFR-ligand expression, we analyzed tumorous mRNA expression in
399 HNSCC patients. The intracellular signaling pathways controlling epidermal growth factor (EGF)-induced
amphiregulin (AREG) expression were examined in three oral squamous cell carcinoma (OSCC) cell lines. Effect of
AREG on cisplatin resistance was examined by viability assays in four-, and by association in 11 OSCC cell lines.
Results: The patients were divided into five groups according to the median mRNA expression levels of four EGFR
ligands, i.e. AREG, EGF, heparin-binding EGF-like growth factor (HBEGF) and beta-cellulin (BTC). The number of
increased-expressed EGFR-ligands were progressively correlated to five-year survival, even in advanced TNM-stage IV
patients, where five-year mortality increased from 26 % if tumor expressed none to one EGFR-ligand, to 45 % in
three to four ligand expressing tumors. Thus, staging the tumor according to these EGFR-ligand mRNA expression
pattern completely out performed TNM staging in predicting prognosis. Multivariate analysis identified AREG as the
dominating predictor, and AREG was overexpressed in OSCC compared to tumors from other sites. Both EGF and
HBEGF stimulation induced strong AREG increase in OSCC cell lines, which was partially mediated by the
extracellular signal-regulated kinase 1/2 pathway, and negatively regulated by p38, c-Jun N-terminal kinase, and
phosphoinositide-3 kinase. Although increased AREG mRNA expression predicted unfavorable prognosis in platinum
treated HNSCC patients, AREG did not mediate cisplatin resistance in the OSCC cell lines.
Conclusions: Increased tumorous mRNA expression of four EGFR ligands was progressively associated with poor
prognosis in HNSCC. Thus, EGFR-ligands mRNA expression pattern may be a new prognostic biomarker. The tightly
regulated EGF-induced AREG mRNA expression was partly lost in the OSCC cell lines and restoring its regulation
may be a new target in cancer treatment.
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Background
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common carcinoma globally [1], with the
oral cavity, pharynx and larynx as the most common
sites [2]. Despite advances in new therapies, five-year
survival rate still remains ~50 % [1].
The majority of epithelial malignancies, including
HNSCC have increased expression and activation
of epidermal growth factor receptor (EGFR) [3], which
is associated with poor prognosis and resistance to
chemo-and radio-therapy [4]. The EGFR ligands:
epidermal growth factor (EGF), transforming growth
factor-α (TGFA), heparin-binding EGF-like growth
factor (HBEGF), amphiregulin (AREG), beta-cellulin
(BTC), epiregulin (EREG) and epigen (EPGN), may
increase tumor growth, invasion, and metastasis
through EGFR activation [5]. These ligands and/or the
receptor are often deregulated in cancers [6], resulting
in increased tumor survival through auto- or paracrine
stimulation [7].
Among the ligands, AREG modulates cell prolifera-
tion, apoptosis and migration of different cell types
including epithelial cells, fibroblasts and immune cells
[8] by binding to and inducing EGFR homo-, or hetero-
dimerization with ErbB2, ErbB3 or ErbB4. This EGFR
activation triggers an intracellular signal cascade through
both the mitogen- activated protein kinases (MAPK)
pathways, the extracellular signal-regulated kinase
(ERK)1/2, the Jun N-terminal kinase (JNK), the p38, and
the phosphoinositide 3-kinase/protein kinase B (PI3K/
Akt) pathways [9].
Although AREG was first described to inhibit growth
of aggressive carcinoma cell lines [10], it is now defined
as an oncogenic factor as it is up-regulated and related
to poor prognosis in a wide variety of carcinomas,
including ovarian, pancreatic, colorectal, breast, pulmon-
ary, bronchial and bladder carcinomas [11], but its role
in HNSCC remains controversial. Whereas AREG acts
as a tumor promoter for oral squamous cell carcinoma
(OSCC) cells [12], and OSCC tissues have higher AREG
mRNA level than normal gingivae [13], HNSCC patients
have lower AREG serum levels than healthy controls
[14]. Despite conflicting results on cell lines, increased
cancerous AREG expression has been associated with
radiotherapy resistance in pancreatic cancer cell lines
[15] and in K-RAS mutated cancer cells, probably by
activating the PI3K-Akt survival pathway [16]. Moreover,
increased AREG expression may be linked to cisplatin
resistance in mammary cancer [17] and HepG2 hepa-
toma cell lines [18], but not in pulmonary cancer [17] or
HNSCC cell lines [19].
Numerous endogenous and exogenous stimuli (EGF,
interleukin 1α, tumor necrosis factor-β, gastrin, insulin
etc., for reference, see review [11]) may induce AREG in
cancer cells, but the intracellular signaling pathway
controlling AREG expression is rather unknown. In our
study, EGF and HBEGF induced strong AREG increase,
which then was used to investigate the intracellular
signaling pathways controlling AREG expression. As
MAPK and PI3K play a central role in transduction of
signals from EGFR, and the activation of Ras/Raf/MAPK
pathway induces AREG transcription in colon cancer
cells [20], we examined if EGF induce AREG through
these pathways. Moreover, HNSCC mRNA expression of
AREG, EGF, HBEGF and BTC was correlated to five-
year mortality by analyzing data in the cancer genomic
atlas database (TCGA, http://cancergenome.nih.gov/).
Finally, we examined whether AREG expression or
stimulation influenced cisplatin sensitivity in our OSCC
cell lines.
Methods
Clinical data and RNA expression analysis
We searched and downloaded the mRNA expression
profiles and clinical data of 498 HNSCC patients from
the TCGA database: (http://cancergenome.nih.gov/). All
patients, diagnosed and treated during 1997–2014,
were followed until September 30th, 2014. For de-
tailed tumor sample acquisition, see reference [21].
Briefly, tumor specimens were collected at the time
of surgical resection. The patients had received no
chemo-or radiotherapy prior for their disease. Cases
were staged according to the American Joint Commit-
tee on Cancer (AJCC), Seventh Edition [22]. mRNA
expression profiles were estimated by normalizing raw
counts of mapped RNA-sequences reads to human
reference genes, and mRNA levels measured as
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fragments per kilobase per million mapped reads
(FPKM). Patients without follow-up data or who died
within two months of operation were excluded, and
finally 399 patients were included in the study.
Reagents
Cisplatin, human recombinant EGF, amphiregulin and
phosphatase-conjugated anti-rabbit IgG antibody were
obtained from Sigma-Aldrich (St. Louis, Missouri, USA).
Anti-human phospho-Erk1/2, phospho-p38, phospho-
JNK, phospho-ErbB2 (Tyr1248), Erk1/2, p38, JNK, Akt,
ErbB2 and EGFR antibodies were obtained from Cell
signaling (Beverly, Massachusetts, USA). Human re-
combinant HBEGF and human amphiregulin ELISA
Duoset were purchased from R&D Systems (Minneapolis,
MN, USA). Anti-human phospho-Akt (Ser 473) antibody
and EGF Receptor (activated) antibody were obtained
from Santa Cruz (Dallas, Texas, USA) and Chemicon
(Billerica, MA, USA), respectively. Phosphatase-conjugated
anti-mouse IgG antibody was purchased from Dako
(Glostrup, Denmark).
EGFR inhibitor AG1478 and ErbB2 inhibitor AG825
were obtained from Sigma-Aldrich; MEK inhibitor
PD98059, p38 inhibitor SB203580, JNK inhibitor SP600125,
and PI3K inhibitor LY294002 were obtained from
Calbiochem (Billerica, MA, USA). All the inhibitors were
diluted in DMSO (Sigma-Aldrich). The specificity of kinase
inhibitors (except for AG825 and PD98059) has been
checked through in vitro radiometric filter binding assays
by the National Centre for Protein Kinase Profiling, MRC
Protein Phosphorylation Unit, University of Dundee,
Scotland, UK (http://www.kinase-screen.mrc.ac.uk). The
selective EGFR inhibitor AG1478 may, in addition inhibit
HER4, however, this did not influence our results as HER4
is not expressed in the cell lines [23].
Cell lines
Eleven human HNSCC cell lines were used in the study.
PE/CA-PJ15 clone B11 (male, 45 years), PE/CA-PJ46 clone
B5 (male, 63 years), and PE/CA-PJ49 clone D12 and clone
E10 (male, 55 years) were established from tongue tissue;
PE/CA-PJ34 clone C12 (basaloid type of OSCC, male,
60 years) and PE/CA-PJ41 clone D2 (female, 68 years) were
derived from the oral cavity and the oral squamous
epithelium, respectively. The cisplatin resistant subclones,
C12cis and D2cis, were selected by exposure to sequential
cycles of cisplatin for eight months, which mimic the way
the drug is used in the clinic [24]. The above six original cell
lines (a kind gift from Dr. A. Berndt and Dr. H. Kosmehl,
Friedrich–Schiller University, Germany) and two in house
made, cisplatin resistant cell lines were cultured under
standard condition as previously described [24]. The
remaining three cell lines, H376 (female, 40 years) from floor
of the mouth, H413 (female, 53 years) from the buccal
mucosa and SCC9 (male, 25 years) from tongue (all from
ECACC, Salisbury, UK), were cultured in Dulbecco’s modi-
fied Eagle’s medium: Ham’s F12 (1:1) (Sigma-Aldrich),
2 mM L-Glutamine, 10 % fetal bovine serum (FBS), 0.5 μg/
ml sodium hydrocortisone succinate (Sigma-Aldrich) and
penicillin-streptomycin, at 37 °C and 5 % CO2.
Cell viability assay
Cells were seeded at a density of 4000 cells per well
in 96-well microtiter plates (Nunc, Wiesbaden-Biebrich,
Germany) in 100 μl culture medium with 10 % FBS per well
in quintuplicate. After 24 h, culture medium was exchanged
to medium with 10 % FBS and different concentration of
cisplatin or growth factors. Cells were further grown for
72 h, before incubated in 50 μl XTT labeling mixture
(Roche Molecular Biochemicals, Mannheim, Germany)
for four h, and then scanned at 450 nm in an Epoch
Microplate Spectrophotometer (BioTek, Winooski, USA).
Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
Cells were serum-starved overnight and inhibitors or
solvent alone were applied one h prior to EGF-
stimulation. Cells were stimulated with 25 ng/ml EGF or
left unstimulated, for four h prior to harvesting.
Total RNA was extracted using RNeasy kit (QIAGEN,
USA), and complementary DNA (cDNA) was synthe-
sized by RT-RTCK-05 kit (Eurogentec, Berlin, Germany)
and stored at −20 °C. A standard real-time PCR reaction
with SYBR green Real MasterMix (Eppendorf, Hamburg,
Germany) was performed in duplicates using Mx3005p
(Agilent Technologies, USA) under the following condi-
tions: 95 °C for 2 min followed by 40 cycles of 95 °C for
20 s, 60 °C for 1 min and 68 °C for 30 s. Dissociation
curves ensured product uniformity. Expression data was
normalized to the housekeeping gene TATA-box binding
protein (TBP). The relative expression levels of the gene
of interest were calculated using the 2-ΔΔCt method.
AREG primers were obtained from Sigma-Aldrich:
forward 5′-GCT-CAG-GCC-ATT-ATG-CTG-CTG-3′,
reverse 5′-ACT-CAC-AGG-GGA-AAT-CTC-ACT-CC-




Cells were incubated with low serum medium (0.1 %)
for 24 h and inhibitors or solvent alone were applied
one h prior to EGF stimulation. Cells were stimulated
with 25 ng/ml EGF or left unstimulated for 5 min. then
harvested and lysed in CelLytic M Cell Lysis Reagent
(Sigma-Aldrich) with protease and phosphatase inhibitor
cocktails (Pierce Biotechnology, IL, Rockford, USA).
Protein concentrations were determined by the Bio-Rad
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protein assay (Bio-Rad, Munich, Germany), and 50 μg
proteins were separated by 10 % casted sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
and electroblotted onto PVDF membranes (Bio-Rad).
After BSA (5 %) blocking for one h, the membranes were
incubated with primary antibodies overnight at 4 °C. The
blots were then washed three times and incubated with
secondary antibodies at room temperature for one h,
washed three times and visualized with ECF substrate (GE
Healthcare, Uppsala, Sweden) in a scanner (Storm, GE
Healthcare).
Enzyme linked immunoassay (ELISA)
The AREG secretion was evaluated using the human
amphiregulin ELISA DuoSet (R&D). Cells were seeded
in 96-well plates at densities of 6000 cells per well.
Duplicate samples were plated for each treatment. The
cells were allowed to attach overnight, then medium was
changed to culture medium with 0.1 % FBS. After
further incubation for 24 h, inhibitors were added one h
prior to stimulation, then supernatant was harvested
after 48 h and directly used in ELISA assay. Absorbance
was read with Epoch Microplate Spectrophotometer
(BioTek), and results were analyzed by Gene 5 software
(BioTek).
Statistics
Statistical analysis was performed using Graphpad prism
6.0 (San Diego, California, USA). The survival
distributions were compared with the log-rank test
(Kaplan–Meier method). Deaths from any cause were
defined as events. The patients were censored at loss to
follow-up, defined as the last date of contact or at
five years after diagnosis. For group differences of nor-
mally distributed data, means were compared using Stu-
dent’s t-test for two categories. Where data were not
normally distributed, medians were compared using
Wilcoxon rank-sum test for two categories or Kruskal-
Willis test for more than three categories. Multivariate
analysis was performed using Cox Regression method.
p values < 0.05 were considered significant.
Results
EGFR ligands mRNA expression predicted poor prognosis
in HNSCC patients
A total of 399 patients, 284 (71 %) men and 115 (29 %)
women, median 61 years (range from 19 to 90), were ad-
mitted in the study. The detailed patients’ information is
shown in Table 1. Dividing patients using median mRNA
expression levels as discriminators revealed that
increased mRNA expression for four EGFR ligands
(AREG, EGF, HBEGF and BTC) was associated with sig-
nificantly reduced five-year survival compared to patients
with lower expression (Fig. 1). Expression of the three
Table 1 Clinical and histological characteristics HNSCC patients
in TCGA database
Characteristic n (%) AREG mRNA levela p valueb
Gender
Male 284 (71) 1249 0.48
Female 115 (29) 1199
Age
≤ 49 68 (17) 238.1 0.28
50–59 112 (28) 193.7
60–69 133 (33) 193.1
≥ 70 86 (22) 188.8
Tumor sites
Oral Cavity 246 (62) 1441 <0.0001***
Lip 2 (1) 129
Oropharynx 55 (14) 552
Larynx 91 (23) 972
Hypopharynx 5 (1) 1516
Tumor pathological stage
I–II 84 (21) 972 0.08
III–IV 259 (65) 1395
Missing 56 (14) 730
Tumor pathological T
T1-T2 141 (35) 1090 0.03*
T3-T4 207 (52) 1402
Missing 51 (13) 780
Tumor pathological N
N0 130 (33) 1312 0.67
N1-3 183 (46) 1352
Missing 86 (21) 759
Tumor histological grade
G1-2 284 (71) 1296 <0.001***
G3-4 103 (26) 1082
GX 12 (3) 369
Smoking history
Smoker 305 (76) 1216 0.83
Non-smoker 84 (22) 1170
Unknown 10 (2) 1482
Alcohol history
Alcohol consumption 273 (68) 973 0.24
No alcohol consumption 119 (30) 1309
Unknown 7 (2) 1517
Human papillomavirus
Positive 18 (4) 55 <0.001***
Negative 66 (17) 807
Unknown 315 (79) 1391
amRNA expression levels were measured as fragments per kilobase per million
mapped reads (FPKM), medians were shown
bGroup differences were compared using Wilcoxon rank-sum test or
Kruskal-Willis test (*p < 0.05, ***p < 0.001)
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other EGFR-ligands (EREG, EPGN and TGFA) was not
linked to prognosis.
Standard algorithms for TNM staging in HNSCC
patients did not predict prognosis, and patients in stage
II and III had similar five-year survival (Fig. 2a). Since
the mRNA expression levels of these four EGFR-ligands
predicted patients outcome separately, we examined if
the number of EGFR ligands with above-median mRNA
expression level predicted the prognosis even better.
Patients were divided into five groups according to number
of ligands with increased tumorous mRNA expression
levels. This revealed a dose-effect pattern with decreased
survival as a function of the number of ligands that were
expressed above median level. Thus, such “molecular
EGFR-ligand staging” predicted patient outcome much
better than the TNM staging system (Fig. 2b). The same
result was observed with patients with TNM stage IV dis-
ease. Whereas only 26 % (14/54) of stage IV patients died
within five years when the HNSCCs expressed increased
mRNA for none or one EGFR-ligand, the number increased
to 32 % (23/71) and 45 % (30/67) if the tumors expressed
increased mRNA for two or more than three EGFR-
ligands, respectively (Fig. 2c). Further analysis in patients
with only “one-ligand” tumors revealed that patients with
over-median AREG-mRNA expression levels had signifi-
cantly increased mortality compared to patients with any of
the other three “single ligand” expressing tumors (Fig. 2d).
Cox multivariate analysis also revealed that AREG
played a predominant role among the four ligands
(Table 2). This was further supported in detailed analysis
of stage IV patients in which AREG expression was associ-
ated with significantly reduced five-year survival (Fig. 2d).
As AREG expression has been associated with cisplatin
resistance in many carcinoma types, we examined AREG
mRNA expression in the 70 cis-/carbo-platin treated
patients and compared it to five-year survival. Patients
with high AREG mRNA levels had poor prognosis despite
cisplatin treatment (Fig. 3a), while this association was not
found with other ligands (not shown). Thus, increased
AREG expression may increase cisplatin resistance in
HNSCC, as reported for mammary cancer cell lines [17].
AREG mRNA level was linked to larger, well differentiated
and human papillomavirus negative tumors
While risk factors such as smoking and alcohol abuse
had no influence on AREG expression level, it was
linked to tumor size and differentiation grade as large
tumors (T3-T4) had higher AREG expression than
smaller tumors (T1-T2) (Table 1), and well-differentiated
tumors (G1-G2) had higher AREG expression than
poorly differentiated tumors (G3-G4) (Table 1). Hu-
man papillomavirus negative (HPV-) tumors also had
higher AREG expression than HPV positive (HPV+)
tumors (Table 1). Moreover, OSCC had higher AREG
Fig. 1 High tumorous mRNA levels of EGFR-ligands predicted poor prognosis in HNSCC patients. HNSCC patients with higher than median
tumorous AREG (a), EGF (b), HBEGF (c) or BTC (d) mRNA levels had lower five-year survival rate compared to patients with lower than median
expression levels (Kaplan-Meier curve, Log rank test). The mRNA levels are measured as fragments per kilobase per million mapped reads (FPKM)
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expression than SCC from oropharynx and larynx
(Table 1), suggesting that AREG expression was particu-
larly deregulated in oral carcinomas. Finally, AREG and
HBEGF expression levels were positively correlated in the
carcinomas (Fig. 3b).
EGF-induced Erk1/2, p38, JNK and Akt pathways
Since cancer extracellular matrix releases EGF and
HBEGF [25], and AREG correlated to HBEGF expression,
we hypothesized that extracellular EGF and/or HBEGF in-
duced AREG overexpression in OSCC. We therefore
treated three OSCC cell lines, C12, D2 and E10, with EGF
and HBEGF and observed that both factors induced
AREG mRNA and protein increase in the same manner
(Fig. 4a). Thus, we used EGF stimulation to examine how
AREG overexpression is controlled in OSCC. As shown in
Fig. 4b, EGF-stimulation induced Erk1/2, p38, JNK, Akt,
EGFR and ErbB2 phosphorylation. The activation of each
Fig. 2 EGFR-ligands-based molecular staging outperforms the TNM system in predicting patient prognosis. a The TNM staging was unable to
predict patients five-year survival (Kaplan-Meier curve, Log rank test, p = 0.08). b Expressing more than median mRNA levels of either none, one,
two, three or four of the EGFR ligands (i.e. AREG, EGF, HBEGF and BCT) was significantly linked to reduced five-year survival (Kaplan-Meier curve,
Log rank test, p < 0.001). Whereas only 14 % of the patients (4/29) with tumors that expressed less than median mRNA levels of the four EGFR
ligands died within five years, the number of death increased as the number of higher-than-median expressing ligands increased to one (25 %,
25/100), two (31 %, 44/142), three (35 %, 34/97) or four (45 %, 14/31). c EGFR-ligand mRNA expression predicted patient survival with TNM stage
IV disease (Kaplan-Meier curve, Log rank test, p = 0.004). Whereas only 26 % (14/54) of patients died within five years if the OSCCs expressed
increased mRNA for none or one of the EGFR-ligands, it increased to 32 % (23/71) and 45 % (30/67) if the tumors expressed increased mRNA
for two, or three to four EGFR-ligands, respectively. d Patients with over-median-AREG-expressing tumors had worse prognosis than patients
expressing any of the other three ligands in the single-ligand-expressing group (Kaplan-Meier curve, Log rank test, p = 0.04)
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of these pathways could be blocked by specific kinase
inhibitors.
Inhibiting EGFR signaling pathways affected EGF-induced
AREG mRNA expression differently
AREG mRNA level showed a peak four h after EGF-
stimulation (Fig. 4a), which was then used to examine
the dynamics in EGF-induced AREG mRNA expression.
Whereas the EGFR-kinase inhibitor (AG1478) attenu-
ated EGF-induced AREG mRNA expression, the ErbB2
kinase inhibitor (AG825) did not (Fig. 5a). Whereas the
MAPK/ERK kinase (MEK) inhibitor (PD98050) reduced
EGF-induced AREG mRNA expression, the PI3K inhibi-
tor (LY294002) increased it in all three cell lines. The
p38 inhibitor (SB203580) revealed a differential response
pattern as it increased EGF-induced AREG mRNA
expression in the cell lines C12 (basaloid SCC) and E10,
only. The JNK-inhibition (SP600125) had similar effect but
only in the two conventional OSCC cell lines D2 and E10.
EGF-induced AREG protein secretion was profoundly
inhibited by ERK1/2 and JNK pathway inhibitors
The EGFR kinase inhibitor, but not the ErbB2 kinase
inhibitor, reduced EGF-induced AREG protein secretion
substantially in all cell lines, except the E10 (Fig. 5b).
Whereas MEK- and JNK-inhibition reduced AREG
secretion in all cell lines, p38 inhibition did not. PI3K-
inhibition partly blocked EGF-induced AREG protein
secretion in the two conventional OSCC cell lines, but
not in the basaloid C12 cell line.
Exogenous EGF or AREG did not increase cisplatin
resistance
Patients with high AREG expression had poor clinical
response to cisplatin treatment (Fig. 3a), suggesting that
AREG increased cisplatin resistance in the HNSCC, as
revealed for several other carcinoma types [17, 18].
However, neither EGF nor AREG increased cisplatin
resistance in any of the four cisplatin sensitive cell lines
(Fig. 6a). Moreover, neither AREG mRNA nor protein
expression was associated with cisplatin resistance in the
11 OSCC cell lines (Fig. 6b), and cisplatin treatment did
Table 2 Univariate and multivariate overall survival analysis of
epidermal growth factor receptor (EGFR) ligands in 399 HNSCC
patientsa
Univariate analysis Multivariate analysis
Factorsb p HR (95%CI)c p HR (95%CI)
EGF 0.008 1.635 (1.139–2.348) 0.002 1.776 (1.233–2.559)
HBEGF 0.034 1.477 (1.031–2.116) 0.32 1.218 (0.828–1.793)
TGFA 0.20 1.583 (0.882–1.806)
AREG 0.002 1.759 (1.227–2.522) 0.001 1.857 (1.257–2.743)
BTC 0.006 1.662 (1.157–2.386) 0.002 1.778 (1.233–2.564)
EPGN 0.23 0.802 (0.562–1.145)
EREG 0.28 1.218 (0.852–1.757)
aLog-rank test was used in univariate analysis and Cox Regression method was
used in multivariate analysis
bmRNA expression levels were measured as fragments per kilobase per million
mapped reads (FPKM) and median mRNA expression levels were used as
discriminators (epidermal growth factor (EGF): 17.88 FPKM; heparin-binding
EGF-like growth factor (HB-EGF): 1274 FPKM; transforming growth factor-α
(TGFA): 1695 FPKM; amphiregulin (AREG): 658 FPKM; beta-cellulin (BTC): 4
FPKM; epigen (EPGN): 32.5 FPKM; epiregulin (EREG): 350 FPKM), and the
groups of patients with lower expression levels were set as reference
cHR, Hazard ratio. 95 % CI, 95 % confidence interval
Fig. 3 Increased tumorous AREG expressing was associated with poor prognosis and with increased HBGEF expression. a Whereas only 7.5 %
(3/40) of cis-/carbo-platin treated patients with lower than median tumorous AREG mRNA levels died within 20 months, 26.7 % (8/30) patients
with higher levels died (Kaplan-Meier curve, Log rank test, p = 0.007). b Tumorous AREG mRNA expression was correlated to HBGEF mRNA
expression, only (p < 0.001; r = 0.54, Spearman correlation analysis)
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not change the AREG mRNA expression or secretion
(data not shown).
Discussion
Pathological based TNM staging uses a combination of
primary tumor size (T), regional lymph node spread (N),
and distant metastases (M), and is currently the domin-
ating system to determine treatments and prognosis in
HNSCC patients. However, the TNM staging system is
rather unreliable in predicting prognosis and is, there-
fore, often combined with biological markers to further
subdivide the cancer, such as prostate-specific antigen
(PSA) in prostate cancer, estrogen receptor (ER), proges-
terone receptor (PR), and ErbB2 in breast cancer [26].
The biomarkers reflect fundamental biological cancer
features that may predict treatment responses and prog-
nosis better than conventional TNM staging does alone.
Here we report, apparently for the first time, that
increased mRNA expression levels of the EGFR ligands
(AREG, EGF, HBEGF and BTC) predicted prognosis in an
almost dose-ligand number dependent manner, and this
predicted prognosis far better than the TNM system.
The EGFR ligands not only have different affinity for
the receptor [27], but there is a dose- modulated ligand-
specific response [28, 29]. These are partly mediated by
ligand-specific phosphorylation of tyrosine residues in
the EGFR [30]. The ligands has been placed in three
groups based on ensemble clustering of their overall
response: Group 1) EGF, AREG and EPR; group 2) BTC,
TGFA and EPG; and group 3) HBEGF [29]. This may
explain why patients with tumors that expressed
increased mRNA levels for EGFR-ligands in all three
response groups: Gr.1 (AREG, EGF), Gr.2 (BTC), and
Gr. 3 (HBEGF) had particular poor prognosis, as this
activated all EGFR-inducible intracellular signaling
pathways.
The EGFR was highly expressed in our cell lines [23],
despite having only one copy of an un-mutated EGFR
gene [31]. Screening of EGFR-ligand mRNA expression
revealed that AREG was considerably higher expressed
Fig. 4 EGF and HBEGF induced AREG expression and actuated MAPK and PI3K/Akt pathways in OSCC cell lines. a Both EGF and HBEGF
stimulated AREG mRNA expression after two h, peaked at four h and disappeared after 24 h (left panel, Student’s t-test, ***p < 0.001). This was
accompanied by increased AREG protein concentration in the supernatant during the following 48 h (right panel; untreated cells were used as
control group; Student’s t-test, ***p < 0.001). A representative experiments in the D2 cell line is shown. b EGF induced phosphorylation of the EGF
receptor, ERK, p38, JNK, Akt and ErbB2 could be completely inhibited by specific kinase inhibitors. Western blotting from a representative
experiment using the D2 cell line
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than any other EGF family members (data not shown),
similar to what the multivariate analysis revealed in the
patients. In addition, patients with increased AREG
levels only, had significantly reduced prognosis com-
pared to those with increased EGF, HBEGF or BTC,
only. Thus, AREG may be a particular important EGFR
ligand in cancer biology.
Cancer associated fibroblasts disrupt extracellular
matrix to generate a track for carcinoma cells to follow
[32]. Such process releases growth factors (i. e. EGF and
HB-EGF), stored in the extracellular matrix, which then
would induce increased cancer cell proliferation [25] and
EGF/HB-EGF induced AREG expression as shown in
this study, which would enhance AREG induced infiltra-
tive behavior and facilitate metastasis.
Interestingly, although EGF stimulation increased AREG
protein secretion in the cancer cell lines, in a human gin-
gival progenitor cell line (HGEPp) and in a transformed
Fig. 5 The intracellular pathways in EGF-induced AREG expression. The EGF-induced AREG mRNA (a) and protein (b) expression was reduced after
EGFR-kinase inhibition in all cell lines, while it showed no reduction after ErbB2-kinase inhibition and was differently affected by the MAPK
inhibitors. a Whereas MEK-inhibition reduced EGF-induced AREG mRNA expression in all the three cell lines, p38- and JNK-inhibition did not.
PI3K-inhibition increased EGF-induced AREG expression in all cell lines. b EGF-induced AREG protein secretion could be totally blocked by
EGFR- inhibition. Whereas MEK- and JNK-inhibition profoundly decrease EGF-induced AREG expression in all cell lines, p38-inhibition had no effect.
The PI3K-inhibitor reduced EGF-induced AREG production in the conventional OSCC cell line D2 and E10, but had no effect on the basaloid OSSC
cell line C12. The ErbB-2- inhibition inhibited the AREG increase in E10 cell line, only. *represents significant difference with EGF stimulation
groups without inhibitors (student’s t-test)
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immortalized keratinocytes cell line (HaCaT), it did not
increase AREG secretion in normal primary oral keratino-
cyte cell lines (Gao et al., unpublished data). Thus, EGF-
induced AREG secretion may be a very tightly regulated
process in normal cells presumably through the same three
intracellular signaling pathways (p38, JNK, and PI3K) that
regulated EGF-induced AREG secretion in OSCC and
transformed cells. The transformed and the OSCC cell lines
had lost at least one of these regulatory pathways (Fig. 7),
allowing EGF-stimulation to increase AREG production.
Losing one of these AREG-regulatory pathways may, there-
fore, be a fundamental process in carcinogenesis.
Both EGF- and HBEGF- induced AREG may increase
cell proliferation, anchorage-independent growth, and
reduce apoptosis in an almost autocrine manner, as
shown for hepatocellular carcinoma [33]. Furthermore,
EGFR-stimulation induces COX-2 and PGE2 production
in OSCC cell lines [34], which may further increase
AREG expression due to EGFR-cross activation, as
shown for colon cancer cell lines [35]. EGFR activation
induced phosphorylation of the PI3K-, and the three
MAPK-pathways with different roles in the EGF-induced
AREG expression. MEK inhibition substantially reduced
EGF-induced AREG mRNA and protein expression in
all three cell lines, illustrating a more total ERK1/2 path-
way dependency than previously observed in human skin
organ cultures [36]. In contrast to insulin-induced AREG
mRNA expression in RT4 bladder cancer cells [37],
PI3K inhibition increased EGF-induced AREG mRNA
expression, but not protein secretion. Thus, PI3K may
regulate AREG mRNA transcription and/or intracellular
AREG trafficking [35].
In addition to PI3K, the two stress-activated MAPKs,
JNK and p38, negatively regulated EGF-induced AREG
mRNA. This could have been through negative regulation
of the ERK1/2 pathway, either through an unknown
mechanism (JNK) or through activation of the phosphatase
PP2A (p38) [38]. Interestingly, cisplatin treated breast
cancer cells overexpressed phospho-ERK1 and expressed
increasingly more AREG as cisplatin resistance developed
[17]. In addition, surviving cisplatin sensitive ovarian cancer
cells had sustained JNK and p38 activation after cisplatin
Fig. 6 Cisplatin resistance was independent of AREG expression in 11 OSCC cell lines. a Neither exogenous EGF nor AREG affected cisplatin
resistance in OSCC cell lines. Cells were grown in the presence (+) or absence (−) of human recombinant EGF (50 ng/ml), human recombinant
AREG (100 ng/ml) for 24 h and then treated with (+) or without (−) 10 μM cisplatin (NS: not significant. p > 0.05, student’s t-test). b Cisplatin IC50
value did not correlate to AREG mRNA expression (left) or protein production (right) in 11 OSCC cell lines. The cisplatin IC50 value in sensitive
(n = 4) or resistant (n = 7) OSCC cell lines were plotted against AREG mRNA expression (left) or 24 h AREG production (right). The cell lines were
clustered into cisplatin sensitive (IC50 < 3.5 μM) or resistant (IC50 > 8.5 μM). Median indicated with horizontal lines (Wilcoxon rank-sum test)
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treatment [39]. However, despite several reports showing a
potential link between cisplatin resistance and increased
AREG expression in various cancers [17, 18], AREG expres-
sion levels did not correlate to cisplatin resistance in the
current 11 OSCC cell lines. Furthermore, exogenous AREG
did not increase cisplatin resistance in the sensitive cell
lines, and the two in house made cisplatin-resistant cell
lines had either increased (C12cis) or decreased (D2cis)
AREG mRNA expression. No other EGFR ligands were
increased in the two in house made cisplatin resistant cell
lines (unpublished data), suggesting that cisplatin resistance
was not mediated by any of these growth factors alone.
Although most of the cis-/carbo-platin treated patients had
advanced disease (TNM stage IV), patients with high
AREG expressing tumors had, in particular, perineural,
lymphovascular and nodal extracapsular infiltration. This
may reflect AREG induced increased cancer cell motility,
migration and infiltrative growth, which may explain the
poor prognosis as AREG did not inhibit cisplatin
cytotoxicity.
Conclusions
Increased tumorous mRNA expression of up to four
EGFR ligands was progressively associated with poor
prognosis in HNSCC. Thus, this may be a new prognos-
tic biomarker in monitoring patients as it was superior
to the TNM staging system. EGF stimulated AREG
production was tightly regulated in normal and trans-
formed cell lines, suggesting that failure to control EGFR
induced AREG expression may be a crucial step in
carcinogenesis and cancer progression. Inhibiting
EGF-induced AREG expression may be a novel strategy
in HNSCC treatment.
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